Nation
World
Politics
Sports
Business
Entertainment
Life
Tech
Science
Opinion
Crime
Health
Oddities

ADC Therapeutics Announce Voluntary Pause Of Patient Enrollment In Phase 2 LOTIS-9 Trial Of ZYNLONTA

Por: RTTNews Health July 11, 2023

thumbnail

ADC Therapeutics SA () announced Tuesday a voluntary pause in the enrollment of new patients in the Phase 2 LOTIS-9 clinical trial evaluating ZYNLONTA (loncastuximab tesirine-lpyl) and rituximab (Lonca-R) in unfit or frail patients with previously untreated diffuse large B-cell lymphoma (DLBCL).The voluntary action was taken by the Company after a recent review of aggregate data of the 40 patients enrolled in the trial and consultation with the... + full article



Similar News

College Enrollment Holds Steady This Spring, Community Colleges See Increase, Says New Report

Forbes USA Business March 29, 2023

thumbnailPreliminary data suggest that overall college enrollment remained steady this spring compared to ... [+] last year. getty Modest though it may be, there’s finally some good news on the college enrollment front. Enrollment at community colleges increased this spring by 2.1%... + más

Biden’s free college proposal is dead. High schoolers are tapping a solution. | Politico

Biden’s free college proposal is dead. High schoolers are tapping a solution. | Politico


Pfizer buys Seagen for $43B, boosts access to cancer drugs

ABC News USA Business March 13, 2023

thumbnailPfizer is spending about $43 billion to reach deeper into new cancer treatments that target tumor cells while sparing surrounding healthy tissue.The pharmaceutical giant said Monday it will pay $229 in cash for each share of Seagen Inc. Pfizer then plans to let the biotech drug... + más

Pfizer buys Seagen for $43B, boosts access to cancer drugs | ABC News

Pfizer buys Seagen for $43B, boosts access to cancer drugs | The Advocate


Pfizer buys Seagen for $43B, boosts access to cancer drugs

ABC News USA Health March 13, 2023

thumbnailPfizer is spending about $43 billion to reach deeper into new cancer treatments that target tumor cells while sparing surrounding healthy tissue.The pharmaceutical giant said Monday it will pay $229 in cash for each share of Seagen Inc. Pfizer then plans to let the biotech drug... + más

Pfizer buys Seagen for $43B, boosts access to cancer drugs | ABC News

Pfizer buys Seagen for $43B, boosts access to cancer drugs | The Advocate


Pfizer buys Seagen for $43B, boosts access to cancer drugs

Associated Press USA Health March 13, 2023

Pfizer is spending about $43 billion to reach deeper into new cancer treatments that target tumor cells while sparing surrounding healthy tissue.The pharmaceutical giant said Monday it will pay $229 in cash for each share of Seagen Inc. Pfizer then plans to let the biotech drug... + más

Pfizer buys Seagen for $43B, boosts access to cancer drugs | ABC News

Pfizer buys Seagen for $43B, boosts access to cancer drugs | ABC News


Biden’s free college proposal is dead. High schoolers are tapping a solution.

Politico USA Business March 12, 2023

thumbnailThere’s a two-for-one special that’s become a popular tactic for teens looking to lower the cost of a college degree: dual enrollment programs. Community colleges saw a 12 percent spike this academic year in these programs, which allow high school students to take their... + más

Where to eat in the dead of winter in R.I. | The Boston Globe

Georgia releases school data, but no grades for third year | Associated Press


Biden’s free college proposal is dead. High schoolers are tapping a solution.

Politico USA Politics March 12, 2023

thumbnailThere’s a two-for-one special that’s become a popular tactic for teens looking to lower the cost of a college degree: dual enrollment programs. Community colleges saw a 12 percent spike this academic year in these programs, which allow high school students to take their... + más

Where to eat in the dead of winter in R.I. | The Boston Globe

Georgia releases school data, but no grades for third year | Associated Press


Can ADC Therapeutics Strike Gold With Lymphoma Drug Zynlonta?

RTTNews USA Health January 18, 2023

thumbnailThis commercial-stage biotechnology company developing next-generation, targeted antibody drug conjugates is aiming to achieve double-digit year-over-year revenue growth for its lead drug.The company we are profiling today is ADC Therapeutics SA () and the drug in focus is... + más

Nkarta | RTTNews

Chicago White Sox pitcher Liam Hendriks says he will undergo cancer treatment after being diagnosed with non-Hodgkin's lymphoma | CBS News



About iurex | Privacy Policy | Disclaimer |